达格列净对射血分数轻度降低或保留的心力衰竭患者肾脏结局的影响:DELIVER随机临床试验的预设分析
该预设分析基于DELIVER随机临床试验,纳入6262例射血分数>40%且eGFR≥25 mL/min/1.73 m2的心力衰竭患者,评估达格列净10 mg/日对心血管和肾脏结局的影响及基线肾脏疾病的作用。结果显示基线肾功能不影响达格列净对主要结局的获益,达格列净未显著减少肾脏复合结局(发生率低),但减缓了eGFR下降。
要点
- 达格列净未显著降低肾脏复合结局(HR 1.08,95%CI 0.79-1.49)。
- 达格列净减缓eGFR年下降率(差异0.5 mL/min/1.73 m2/年)。
核心结论
- 基线肾功能未改变达格列净在射血分数轻度降低或保留的心力衰竭患者中的获益。
- 达格列净未显著减少肾脏复合结局,但减缓了eGFR下降速率。
研究设计与样本
- DELIVER随机临床试验的预设分析,于2022年7月1日至9月18日进行。
- 国际多中心试验,纳入射血分数>40%且eGFR≥25 mL/min/1.73 m2的患者。
- 共6262例患者,平均年龄72岁,56%为男性,平均eGFR 61 mL/min/1.73 m2,49%患者eGFR<60 mL/min/1.73 m2。
- 干预为达格列净10 mg/日或安慰剂。
主要发现
- 中位随访2.3年(IQR 1.7-2.8),肾脏复合结局总体发生率低(1.1事件/100患者年),达格列净未显著影响(HR 1.08,95%CI 0.79-1.49)。
临床怎么用
- 对于射血分数轻度降低或保留的心力衰竭患者,达格列净的心血管获益不受基线肾功能影响。
- 达格列净可减缓eGFR下降,支持其肾脏保护作用。
- 肾脏复合结局发生率低,达格列净未显著减少该结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sodium-glucose cotransporter 2 inhibitors are known to reduce heart failure events and slow progression of kidney disease among patients with heart failure and a reduced ejection fraction. OBJECTIVE: To determine the effect of dapagliflozin on cardiovascular and kidney outcomes and the influence of baseline kidney disease among patients with heart failure and a mildly reduced or preserved ejection fraction enrolled in the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified analysis conducted from July 1 to September 18, 2022 of the DELIVER randomized clinical trial. This was an international, multicenter trial including patients with ejection fraction greater than 40% and estimated glomerular filtration rate (eGFR) of 25 mL/min/1.73 m2 or higher. INTERVENTIONS: Dapagliflozin, 10 mg, per day or placebo. MAIN OUTCOMES AND MEASURES: Outcomes assessed were whether baseline kidney function modified the treatment effect on the primary outcome (cardiovascular death or worsening heart failure). Also examined was the treatment effect on the prespecified outcomes of eGFR slope and a post hoc composite kidney outcome (first ≥50% decline in eGFR from baseline; first eGFR <15 mL/min/1.73 m2; end-stage kidney disease; death from kidney causes). RESULTS: A total of 6262 patients (mean [SD] age, 72 [10] years; 3516 male [56%]) had mean (SD) eGFR measurements available: 61 (19) mL/min/1.73 m2; 3070 patients (49%) had an eGFR less than 60 mL/min/1.73 m2. The effect of dapagliflozin on the primary outcome was not influenced by baseline eGFR category (eGFR ≥60 mL/min/1.73 m2: hazard ratio [HR], 0.84; 95% CI, 0.70-1.00; eGFR 45-<60 mL/min/1.73 m2: HR, 0.68; 95% CI, 0.54-0.87; eGFR <45 mL/min/1.73 m2: HR, 0.93; 95% CI, 0.76-1.14; P for interaction = .16). Over a median (IQR) follow-up of 2.3 (1.7-2.8) years, the overall incidence rate of the kidney composite outcome was low (1.1 events per 100 patient-years) and was not affected by treatment with dapagliflozin (HR, 1.08; 95% CI, 0.79-1.49). However, dapagliflozin attenuated the decline in eGFR from baseline (difference, 0.5; 95% CI, 0.1-0.9 mL/min/1.73 m2 per year; P = .01) and from month 1 to 36 (difference, 1.4; 95% CI, 1.0-1.8) mL/min/1.73 m2 per year; P < .001). CONCLUSIONS AND RELEVANCE: Results of this prespecified analysis showed that baseline kidney function did not modify the benefit of dapagliflozin in patients with heart failure and a mildly reduced or preserved ejection fraction. Dapagliflozin did not significantly reduce the frequency of the kidney composite outcome, although the overall event rate was low. However, dapagliflozin slowed the rate of decline in eGFR compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213.
引用
- Mc Causland, Claggett, Vaduganathan, et al. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 36326604. doi:10.1001/jamacardio.2022.4210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。